Penumbra reports 22% revenue surge in final quarter
Penumbra (NYSE:PEN), a global leader in thrombectomy technology, reported a surge in fourth-quarter revenue that exceeded its own raised forecasts, capping a year that will culminate in the company’s acquisition by Boston Scientific Corp. (NYSE:BSX).







-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)

